Details of Disease

General Information of Disease (ID: DISU8N7X)

Disease Name	Metabolic syndrome x
Synonyms	abdominal obesity metabolic syndrome; abdominal obesity-metabolic syndrome quantitative trait locus 1; metabolic syndrome 10; metabolic syndrome, protection against; AOMS1; dysmetabolic syndrome X; metabolic syndrome type X; abdominal obesity-metabolic syndrome 1
Disease Class	5C50-5D2Z: Metabolic disorder
Disease Hierarchy	DISPSIVN: Abdominal obesity-metabolic syndrome DISU8N7X: Metabolic syndrome x
ICD Code	ICD-11 ICD-11: 5C50-5D2Z
Disease Identifiers	MONDO ID MONDO_0011565 UMLS CUI C4552048 OMIM ID 605552 MedGen ID 1640883

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Topiramate	DM82Z30	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
S-474474	DM408GM	Phase 3	NA	[2]
Fucoxanthin	DMPQFTA	Phase 2	NA	[3]
URSOLIC ACID	DM4SOAW	Phase 2	Small molecular drug	[4]
ISIS-APOCIII	DMX3FN4	Phase 1	Antisense drug	[5]
NP-500	DMHARE7	Phase 1	NA	[6]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SKI-2852	DMJL6HX	Investigative	NA	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	Topiramate FDA Label
2	Clinical pipeline report, company report or official report of Shionogi (2011).
3	ClinicalTrials.gov (NCT03613740) Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT02337933) Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024901)
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763).